n*n
2 楼
富马酸二甲酯,
这么简单的药物,当初怎么发现的?
专利没有问题吗
这么简单的药物,当初怎么发现的?
专利没有问题吗
p*u
4 楼
Dimethyl fumarate has won FDA approval to treat relapsing-remitting forms of
multiple sclerosis and will be sold under the name Tecfidera, the agency
said Wednesday.
Manufactured by Biogen Idec, the drug is also known as BG-12. It becomes the
third oral disease-modifying medication available to treat MS. Others
include fingolimod (Gilenya) and teriflunomide (Aubagio).
Dimethyl fumarate has a novel mechanism of action relative to existing MS
drugs. It is believed to activate the nuclear factor-like 2 transcriptional
pathway, thereby reducing oxidative stress that contributes strongly to
demyelination.
The drug has also been used for many years in Europe and elsewhere to treat
psoriasis, and has also been used as a fungicide and desiccant in furniture
manufacture.
Two placebo-controlled phase III trials served as the basis for approval,
the agency said. Called DEFINE and CONFIRM, they enrolled a total of some 2,
700 patients. In addition to comparing the drug with placebo, CONFIRM
included a third arm with open-label glatiramer acetate (Copaxone), a
standard injectable MS drug.
Both trials demonstrated that dimethyl fumarate was superior to placebo in
preventing relapses and delaying disability progression. It also appeared to
be somewhat more effective than glatiramer acetate in CONFIRM.
The most common adverse effects were gastrointestinal complaints and
flushing. The FDA also noted that the drug carries a risk of lymphocytopenia
, although infections did not appear to be increased as a result in the
phase III studies.
"No drug provides a cure for multiple sclerosis so it is important to have a
variety of treatment options available for patients," said Russell Katz, MD
, director of the Division of Neurology Products in the FDA's Center for
Drug Evaluation and Research, in a statement announcing the approval.
A Biogen competitor, Teva Pharmaceuticals, had petitioned the FDA to hold an
advisory committee meeting on the drug before approving it, citing the
hematologic effects and other risks, but the agency declined to do so.
http://www.medpagetoday.com/Neurology/MultipleSclerosis/38122?i
multiple sclerosis and will be sold under the name Tecfidera, the agency
said Wednesday.
Manufactured by Biogen Idec, the drug is also known as BG-12. It becomes the
third oral disease-modifying medication available to treat MS. Others
include fingolimod (Gilenya) and teriflunomide (Aubagio).
Dimethyl fumarate has a novel mechanism of action relative to existing MS
drugs. It is believed to activate the nuclear factor-like 2 transcriptional
pathway, thereby reducing oxidative stress that contributes strongly to
demyelination.
The drug has also been used for many years in Europe and elsewhere to treat
psoriasis, and has also been used as a fungicide and desiccant in furniture
manufacture.
Two placebo-controlled phase III trials served as the basis for approval,
the agency said. Called DEFINE and CONFIRM, they enrolled a total of some 2,
700 patients. In addition to comparing the drug with placebo, CONFIRM
included a third arm with open-label glatiramer acetate (Copaxone), a
standard injectable MS drug.
Both trials demonstrated that dimethyl fumarate was superior to placebo in
preventing relapses and delaying disability progression. It also appeared to
be somewhat more effective than glatiramer acetate in CONFIRM.
The most common adverse effects were gastrointestinal complaints and
flushing. The FDA also noted that the drug carries a risk of lymphocytopenia
, although infections did not appear to be increased as a result in the
phase III studies.
"No drug provides a cure for multiple sclerosis so it is important to have a
variety of treatment options available for patients," said Russell Katz, MD
, director of the Division of Neurology Products in the FDA's Center for
Drug Evaluation and Research, in a statement announcing the approval.
A Biogen competitor, Teva Pharmaceuticals, had petitioned the FDA to hold an
advisory committee meeting on the drug before approving it, citing the
hematologic effects and other risks, but the agency declined to do so.
http://www.medpagetoday.com/Neurology/MultipleSclerosis/38122?i
b*t
5 楼
等到下个statement也很正常
s*g
7 楼
你确定买的都是grocery店?
c*u
8 楼
walmart到底算不算,有个确切的答案吗
相关阅读
SPR贴图问题小感慨一下求助: t test 什么时候双边,什么时候用单边Hotel sharing at ASGCT 2011 or AAPS biotech 2011急求一篇paper!!! thanks!Paper Help!! From Advances in Chronic Kidney Diseasenmr 做蛋白结构的前途看到学校cell biology的一个faculty candidate资料,觉得好厉害的索。。。请问前辈,工业界是不是没有绿卡就没可能?肿瘤免疫这个领域怎么样?统计盲人就指点有做 Riboswich 的in-line probing 的吗?求助IHC或者IF fixation的方法请教提取细胞核蛋白后WB背景高的问题sos 被针头扎了怎么办paper helppaper help please. Thanks.分析一下美国投重金搞生物研究的原因video of yigong shiNature: No longer a guaranteed ticket to an academic career, the PhD system needs a serious rethink.